all report title image
  • To Be Published : Sep 2023
  • Code : CMI1836
  • Pages : N/A
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Octreotide is an octapeptide that resembles natural somatostatin pharmacologically. Octreotide acetate is widely used in treatment of some types of cancers, diarrhea, and tumors such as carcinoid, pancreatic islet cell tumors, and vasoactive intestinal peptide secreting tumors. Octreotide acetate is also used to treat acromegaly when the body produces excess of growth hormone, which causes enlarged feet, hands, face, and head.

Octreotide Market Drivers:-

Major driver for growth of the Octreotide market is the robust pipeline of drugs in clinical trials. For instance, in 2016, Mario Negri Institute for pharmacological research completed phase 2 clinical trials of its Octreotide LAR in combination with tolvaptan drug for the treatment of autosomal dominant polycystic kidney disease. This disease has an effect on the glomerular rate and total kidney and cystic volume. Octreotide sponsored by Radbound University is in phase 3 clinical trials from 2016. This drug is under clinical trial for the treatment of angiodysplasia, vascular malformations, gastrointestinal hemorrhage, and anemia with Octreotide. Injection Octreotide, sponsored by PVS memorial hospital is in phase 4 clinical trials since 2016. This injection is indicated for treatment of pancreatic fistula and complications of pancreatoduodenectomy among patients with soft pancreas. Furthermore, CAM2029 is being tested, currently in phase 2, for acromegaly and neuroendocrine tumors by Camurus AB in collaboration with Novartis AG. Octreotide chloride is the active ingredient for this product.

Increasing number of launches pertaining to novel Octreotide acetate products by key players in the market is expected to drive market growth. For instance, in 2013, Sagent Pharmaceuticals, a U.S.-based biopharmaceutical company, launched its new drug Octreotide acetate, a samatostatin analog. This drug is used to reduce blood levels of IGF-I (soatomedinC) and growth hormone in acromegaly patients who do not adequately respond to or who cannot be treated by surgery, irradiation and bromocriptine mesylate.

Increasing prevalence of disease such as acromegaly and cancer, is expected to increase the demand for Octreotide drugs, which in turn is expected to fuel market growth. According to a survey conducted by National Institute of Health in 2015, over 4 million people suffer from acromegaly in the U.S.

Lack of research and development for Octreotide acetate for the treatment of children, lactating and pregnant women is a major restraining factor in this market. Moreover, consumption of Octreotide acetate by pregnant women can cause problems in the growth of the fetus and hence, its adoption is limited among pregnant woman.

Octreotide Market Regional Analysis:-

North America is expected to hold a dominant position in the Octreotide market due to the presence of key players and robust pipeline of products in the region. For instance, Octreotide capsules sponsored by Chaisma Inc.—a biopharmaceutical company based in the U.S.—completed phase 3 clinical trials in 2017 for treatment of acromegaly. LAR lanreotide sponsored by Memorial Sloan Kettering Cancer Center, based in New York City, is currently in phase 4 clinical trials since 2016. LAR lanreotide is indicated for treatment of neuroendocrine tumors. Novel drugs are expected to fuel growth of the Octreotide market in North America. For instance, in 2011 Mylan Pharmaceutical Ltd—a generic and pharmaceuticals specialty company based in the U.S.—launched the generic version of sandostatin i.e. Octreotide acetate injection USP (pre-filled syringes). Octreotide acetate injection USP is used to treat acromegaly. It is also used to inhibit and suppress severe diarrhea, which is associated with metastatic carcinoid tumors and vasoactive intestinal peptide tumors.

Europe is expected to show significant growth in the Octreotide market due to strategic mergers and acquisitions among key players. For instance, in 2017, Novartis AG—a Switzerland-based company—acquired Advanced Accelerator Applications, a France-based company—to increase the development of its therapeutics portfolio, which also includes development of Octreotide to cure oncology.

Octreotide Market Key Players:-

Key players operating in the Octreotide market include Samarth Pharma Pvt Ltd., Sun Pharmaceuticals Industries Ltd., Neiss Labs Pvt. Ltd., Novartis AG, and Unique Chemical Ltd. Major players in the market are adopting inorganic growth strategies such as mergers and acquisitions, to strengthen their foothold in the global market. For instance, in 2015, Sun Pharmaceutical Industries Ltd.—Mumbai-based company—acquired Ranbaxy laboratories Ltd.—India-based pharmaceutical company—to enhance its productivity and focus on development of therapeutic area, including development of new drugs of Octreotide acetate. Such strategic acquisition among key players in the market is expected to create a lucrative environment for growth of the Octreotide market in the near future.

Octreotide Market Taxonomy:-

By Product Type:-

  • Octreotide acetate
  • Octreotide chloride
  • Indium In-111; Octreotide
  • Others

By Formulation

  • LAR Depot Form
  • Immediate Release Injection Form

By Application:-

  • Therapeutics (Acromegaly, Tumors and Others)
  • Diagnostics

By Distribution Channel:-

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

By Region:-

  • North America
  • Europe
  • Latin America
  • Asia Pacific
  • Middle East
  • Africa

  • Need a Custom Report?

    We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

    Customize Now
  • Want to Buy a Report but have a Limited Budget?

    We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

    Request Discount

Reliability and Reputation

DUNS Registered
DMCA Protected


Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo